Skip to main content
SpringerLink
Log in

Systemic atenolol exposure may be a risk factor for hyperglycaemia during short-term treatment with atenolol,

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Navare HA, Frye RF, Cooper-DeHoff RM, Shuster JJ, Hall K, Schmidt SO, Turner ST, Johnson JA.Atenolol exposure and risk for development of adverse metabolic effects: a pilot study. Pharmacotherapy 30: 872-878, No. 9, 1 Sep 2010. Available from: URL: http://dx.doi.org/10.1592/phco.30.9.872

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Systemic atenolol exposure may be a risk factor for hyperglycaemia during short-term treatment with atenolol,. React. Wkly. 1327, 2 (2010). https://doi.org/10.2165/00128415-201013270-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201013270-00003

Keywords

Search

Navigation